About CancerVax
CancerVax is a Healthcare company based in Carlsbad (United States) founded in 1998. Cancer vaccine research and development is conducted by CancerVax. CancerVax has raised $55 million across 3 funding rounds from investors including J P Morgan, GE Capital and China Developement Bank. Its chief executive, as recorded, is David Hale. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service. Its competitors include Aster Insights, OnCusp and Oncotherapeutics; 3 of its 3 listed competitors have raised funding.
Company details
CancerVax was established in 1998 and is based in Carlsbad, United States. Operations are centered in the biotechnology sector, specifically oncology and immunotherapy. Focus is placed on developing vaccines targeted at cancer treatment. Research activities are led from the companys headquarters, with David Hale serving as CEO. Limited public details are available regarding specific products or partnerships.
- Headquarters Carlsbad, United States
- SectorsHealthcare
- Email••••••••
- Website cancervax.com
- Social LinkedIn Facebook Instagram YouTube
- Total Equity Funding$55M (USD)
in 3 rounds
- Latest Funding Round$1M (USD), Unspecified
Oct 2023
- InvestorsJ P Morgan
& 11 more
Apps and channels of CancerVax
its YouTube channel CancerVAX has 379 subscribers and 30 videos.
Videos from CancerVax
The most watched videos on CancerVax's YouTube channel, CancerVAX (379 subscribers). Click a video to play it here.
More on CancerVAX.
Funding Insights of CancerVax
CancerVax has successfully raised a total of $55M across 3 strategic funding rounds. The most recent funding activity was a Unspecified round of $1 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $55M
- Total Rounds 3
- Last Round Unspecified — $1M
- First Round $55M
(Apr 2002)
- Investors Count 12
All 3 funding rounds of CancerVax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $1M | Unspecified | – | – | – |
| Jun 2023 | $2M | Unspecified | – | – | – |
| Apr 2002 | $55M | Series C | – | Athenian Venture Partners |
12 investors in total: 12 institutional.
Investors in CancerVax
CancerVax has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, GE Capital and China Developement Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US focused early stage venture capital firm | athenianvp.com | Fort Lauderdale, United States | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Life Sciences & Offline focused early stage VC firm investing in the US | windamerevp.com | San Diego, United States | ||
Life Sciences focused VC firm that does early stage investments in the US | forwardventures.com | San Diego, United States | ||
| vectorfund.com | ||||
| amerindo.com | ||||
Early-stage centric tech focused VC firm funding companies in the US | gmgpartners.net | New York, United States | ||
Comprehensive financial services are provided to corporations and individuals. | 1799 | jpmorgan.com | New York, United States | |
| cdibbiosciencevc.com | ||||
Commercial aircraft and equipment leasing and lending services are provided. | 1932 | gecapital.com | United States |
Investor details for CancerVax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CancerVax
1 people are tracked at CancerVax (1 in leadership).
| Name | Role | Group |
|---|---|---|
David Hale | CEO | Leadership |
Complete people profiles for CancerVax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CancerVax
3 dated milestones of CancerVax across 25 years, from founding to its latest funding, stage changes and deals.
- Founded CancerVax is founded.
- Funding First funding round of $55.0M.
- Funding Latest funding round, Unspecified, of $1.0M.
Competitors of CancerVax
CancerVax has 3 listed competitors in our database, 3 of them funded. They include Aster Insights, OnCusp and Oncotherapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| asterinsights.com | 2006 | Tampa, United States | $75M | 115 | Contract-based oncology clinical trial services are provided by Aster Insights. | |
| oncusptx.com | 2021 | New York, United States | $100M | CRO offering clinical development services for oncology drugs | ||
| oncotherapeutics.com | 1988 | West Hollywood, United States | $8.3M | Preclinical and clinical oncology drug development services are provided. |
Detailed competitors of CancerVax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CancerVax
The website of CancerVax (cancervax.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▼ 41.4% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as CancerVax (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cancervax
Complete news archive for CancerVax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CancerVax
CancerVax was founded in 1998 and raised its 1st funding round 4 years after it was founded.
CancerVax is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
David Hale is the CEO of CancerVax, as recorded in our data.
CancerVax is a funded company, having raised a total of $55M across 3 funding rounds to date. The company's 1st funding round was a Series C of $55M, raised on Apr 2002.
CancerVax was established in 1998 and is based in Carlsbad, United States. Operations are centered in the biotechnology sector, specifically oncology and immunotherapy. Focus is placed on developing vaccines targeted at cancer treatment. Research activities are led from the companys headquarters, with David Hale serving as CEO. Limited public details are available regarding specific products or partnerships.
CancerVax's top competitors include OnCusp, Aster Insights and Oncotherapeutics.
CancerVax has 12 investors. Key investors include J P Morgan, GE Capital, China Developement Bank, Athenian Venture Partners, and SV Health Investors.